These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

392 related articles for article (PubMed ID: 26377630)

  • 1. Omalizumab in patients with eosinophilic granulomatosis with polyangiitis: a 36-month follow-up study.
    Detoraki A; Di Capua L; Varricchi G; Genovese A; Marone G; Spadaro G
    J Asthma; 2016; 53(2):201-6. PubMed ID: 26377630
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Asthma Control and Airway Inflammation in Patients with Eosinophilic Granulomatosis with Polyangiitis.
    Latorre M; Baldini C; Seccia V; Pepe P; Novelli F; Celi A; Bacci E; Cianchetti S; Dente FL; Bombardieri S; Paggiaro P
    J Allergy Clin Immunol Pract; 2016; 4(3):512-9. PubMed ID: 26883543
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-IgE Monoclonal Antibody (Omalizumab) in Refractory and Relapsing Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss): Data on Seventeen Patients.
    Jachiet M; Samson M; Cottin V; Kahn JE; Le Guenno G; Bonniaud P; Devilliers H; Bouillet L; Gondouin A; Makhlouf F; Meaux-Ruault N; Gil H; Bienvenu B; Coste A; Groh M; Giraud V; Dominique S; Godeau B; Puéchal X; Khouatra C; Ruivard M; Le Jeunne C; Mouthon L; Guillevin L; Terrier B;
    Arthritis Rheumatol; 2016 Sep; 68(9):2274-82. PubMed ID: 26946346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term omalizumab treatment in severe allergic asthma: the South-Eastern Mediterranean "real-life" experience.
    Tzortzaki EG; Georgiou A; Kampas D; Lemessios M; Markatos M; Adamidi T; Samara K; Skoula G; Damianaki A; Schiza S; Tzanakis N; Siafakas NM
    Pulm Pharmacol Ther; 2012 Feb; 25(1):77-82. PubMed ID: 22155001
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-life evidence of low-dose mepolizumab efficacy in EGPA: a case series.
    Detoraki A; Tremante E; Poto R; Morelli E; Quaremba G; Granata F; Romano A; Mormile I; Rossi FW; de Paulis A; Spadaro G
    Respir Res; 2021 Jun; 22(1):185. PubMed ID: 34162391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Omalizumab lowers asthma exacerbations, oral corticosteroid intake and blood eosinophils: Results of a 5-YEAR single-centre observational study.
    Pelaia C; Calabrese C; Barbuto S; Busceti MT; Preianò M; Gallelli L; Savino R; Vatrella A; Pelaia G
    Pulm Pharmacol Ther; 2019 Feb; 54():25-30. PubMed ID: 30414440
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The real world effect of omalizumab add on therapy for patients with moderate to severe allergic asthma: The ASTERIX Observational study.
    Bhutani M; Yang WH; Hébert J; de Takacsy F; Stril JL
    PLoS One; 2017; 12(8):e0183869. PubMed ID: 28859150
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of omalizumab in patients with inadequately controlled severe persistent allergic asthma: an open-label study.
    Niven R; Chung KF; Panahloo Z; Blogg M; Ayre G
    Respir Med; 2008 Oct; 102(10):1371-8. PubMed ID: 18657960
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of reslizumab in the treatment of eosinophilic granulomatosis with polyangiitis.
    Manka LA; Guntur VP; Denson JL; Dunn RM; Dollin YT; Strand MJ; Wechsler ME
    Ann Allergy Asthma Immunol; 2021 Jun; 126(6):696-701.e1. PubMed ID: 33548468
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mepolizumab as a glucocorticoid-sparing agent in eosinophilic granulomatosis with polyangiitis (EGPA): is a lower dose sufficient?
    Vergles M; Matković Z; Lalić K; Trkanjec JT; Tudorić N
    J Asthma; 2021 Dec; 58(12):1675-1679. PubMed ID: 32962455
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of long-term omalizumab treatment in patients with severe allergic asthma long-term omalizumab treatment in severe asthma.
    Özgür ES; Özge C; Ïlvan A; Naycı SA
    J Asthma; 2013 Aug; 50(6):687-94. PubMed ID: 23557459
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Omalizumab treatment in patient with severe asthma and Eosinophilic Granulomatosis with Polyangiitis . A case report.
    Graziani A; Quercia O; Girelli F; Martelli A; Mirici Cappa F; Stefanini GF
    Eur Ann Allergy Clin Immunol; 2014 Nov; 46(6):226-8. PubMed ID: 25398166
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Omalizumab in eosinophilic granulomatosis with polyangiitis: friend or foe? A systematic literature review.
    Basta F; Mazzuca C; Nucera E; Schiavino D; Afeltra A; Antonelli Incalzi R
    Clin Exp Rheumatol; 2020; 38 Suppl 124(2):214-220. PubMed ID: 32083537
    [TBL] [Abstract][Full Text] [Related]  

  • 14. "Real-life" Efficacy and Safety Aspects of 4-Year Omalizumab Treatment for Asthma.
    Al-Ahmad M; Arifhodzic N; Nurkic J; Maher A; Rodriguez-Bouza T; Al-Ahmed N; Sadek A; Jusufovic E
    Med Princ Pract; 2018; 27(3):260-266. PubMed ID: 29414831
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dupilumab for relapsing or refractory sinonasal and/or asthma manifestations in eosinophilic granulomatosis with polyangiitis: a European retrospective study.
    Molina B; Padoan R; Urban ML; Novikov P; Caminati M; Taillé C; Néel A; Bouillet L; Fraticelli P; Schleinitz N; Christides C; Moi L; Godeau B; Knight A; Schroeder JW; Marchand-Adam S; Gil H; Cottin V; Durel CA; Gelain E; Lerais B; Ruivard M; Groh M; Samson M; Moroni L; Thiel J; Kernder A; Cohen Tervaert JW; Costanzo G; Folci M; Rizzello S; Cohen P; Emmi G; Terrier B
    Ann Rheum Dis; 2023 Dec; 82(12):1587-1593. PubMed ID: 37734881
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Respiratory manifestations of eosinophilic granulomatosis with polyangiitis (Churg-Strauss).
    Cottin V; Bel E; Bottero P; Dalhoff K; Humbert M; Lazor R; Sinico RA; Sivasothy P; Wechsler ME; Groh M; Marchand-Adam S; Khouatra C; Wallaert B; Taillé C; Delaval P; Cadranel J; Bonniaud P; Prévot G; Hirschi S; Gondouin A; Dunogué B; Chatté G; Briault A; Jayne D; Guillevin L; Cordier JF;
    Eur Respir J; 2016 Nov; 48(5):1429-1441. PubMed ID: 27587545
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Asthma control, lung function, symptoms, and corticosteroid sparing after omalizumab initiation in patients with allergic asthma.
    Pilon D; Kavati A; Ortiz B; Paknis B; Vegesna A; Schiffman B; Zhdanava M; Lefebvre P; Stone B
    Allergy Asthma Proc; 2018 Mar; 39(2):127-135. PubMed ID: 29208079
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sequential rituximab and omalizumab for the treatment of eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome).
    Aguirre-Valencia D; Posso-Osorio I; Bravo JC; Bonilla-Abadía F; Tobón GJ; Cañas CA
    Clin Rheumatol; 2017 Sep; 36(9):2159-2162. PubMed ID: 28762062
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of omalizumab as add-on therapy on asthma-related quality of life in severe allergic asthma: a Brazilian study (QUALITX).
    Rubin AS; Souza-Machado A; Andradre-Lima M; Ferreira F; Honda A; Matozo TM;
    J Asthma; 2012 Apr; 49(3):288-93. PubMed ID: 22356355
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Omalizumab therapy in a 13-year-old boy with severe persistent asthma and concomitant eosinophilic esophagitis.
    Arasi S; Costa S; Magazzù G; Ieni A; Crisafulli G; Caminiti L; Chiera F; Vaccaro M; Del Giudice MM; Pajno GB
    Ital J Pediatr; 2016 Mar; 42():32. PubMed ID: 27000314
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.